MNMDNASDAQHealthcare · Biotechnology

Mind Medicine (MindMed) Inc.

$20.69+0.44%(+$0.09)

TickerSpark Score

57/100

Mixed

Valuation

Profitability

Growth

Health

100

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNMD research report →

52-Week Range98% of range

Low $4.70

Current $20.69

High $21.08

Companywww.mindmed.co

Mind Medicine (MindMed) Inc. , a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

CEO: Robert Barrow
IPO: 2016
Employees: 74
HQ: Vancouver, BC, CA

Price Chart

+242.41% · this period

Valuation

Market Cap: $1.56B
P/E: -9.57
P/S: 0.00
P/B: 8.15
EV/EBITDA: -9.77
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -102.48%
ROIC: -60.39%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-183,793,000 · -69.12%
EPS: $-2.06 · -33.77%
Op Income: $-166,309,000
FCF YoY: -66.26%

Performance & Tape

52W High: $21.08
52W Low: $4.70
50D MA: $12.71
200D MA: $9.85
Beta: 2.62
Avg Volume: 2.53M

Get TickerSpark's AI analysis on MNMD

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Jun 1, 22	Makes Brigid	director	other	361,680	$0
Jun 1, 22	Makes Brigid	director	other	100,308	$60.18K
Jun 1, 22	Makes Brigid	director	other	64,656	$0
May 23, 22	Greenway Schond L.	officer: Chief Financial Officer	other	1,650,000	$1.17M
May 23, 22	Greenway Schond L.	officer: Chief Financial Officer	other	1,270,000	$0

Our MNMD Coverage

View all →

ipo_article

Optimi Health Corp. IPO: What to Know Before It Lists

Optimi Health Corp. (NASDAQ: OPTH) is expected to list on 2026-05-20, with a price range not disclosed and 2,500,000 shares offered. The setup is a small, early commercial psychedelic manufacturer with real revenue, but it is still carrying losses, a working capital deficit, and heavy regulatory dependence.

May 20, 2026